Asco Annual Meeting

Also showing items for ASCO Annual

 
News Articles for Asco Annual Meeting top ^
2013/5/15
Exelixis, Inc. (NASDAQ:EXEL) reiterated its slate of activities in conjunction with the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2013, in Chicago, Illinois.
Sign-up for Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting investment picks
2013/5/7
Exelixis, Inc. (NASDAQ:EXEL) announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will be held May 31-June 4, 2013, in Chicago, Illinois.
Sign-up for Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting investment picks
2013/5/15
BOULDER, Colo.
Sign-up for Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting investment picks
2013/5/16
DiagnoCure announces presentation on Previstage GCC at the 2013 ASCO annual meeting Canada NewsWire New findings validate clinical utility in Colorectal Cancer Staging MONTREAL , May 16, 2013 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"), today announced that results from a large validation study of the Previstage TM GCC Colorectal Cancer Staging Test have been selected for presentation at the 2013 American Society of Clinical Oncology ® (ASCO ® ) Annual Meeting, taking place in Chicago , Illinois from May 31 to June 4, 2013 .
Sign-up for DiagnoCure announces presentation on Previstage GCC at the 2013 ASCO annual meeting investment picks
2013/5/16
Final Phase 1 Results Demonstrate Activity in Ovarian and Breast Cancer Phase 3 Trial in Ovarian Cancer to Begin Enrolling Patients by Mid-Year Phase 3 Trial in Patients With Breast Cancer on Track to Initiate in 2H13 WALTHAM, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) , an oncology-focused biopharmaceutical company, today announced that final results from a Phase 1 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Sign-up for TESARO Announces Presentation of Niraparib Clinical Data at the 2013 ASCO Annual Meeting investment picks
2013/5/15
Bristol-Myers Squibb Company (NYSE: BMY) today announced that new data on its approved and investigational immuno-oncology compounds, Yervoy and the investigational PD-1 receptor blocking antibody nivolumab, will be featured in six oral presentations at the 49 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31 - June 4.
Sign-up for Bristol-Myers Squibb Advances Leadership Position in Immuno-Oncology with Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting investment picks
2013/5/16
Clovis Oncology (NASDAQ:CLVS) announced that three abstracts (ASCO Abstracts #2524, #2585, #2586) highlighting results from three Phase I studies of the company’s two lead compounds will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 in Chicago.
Sign-up for Clovis Oncology Announces Clinical Data to be Presented at ASCO Annual Meeting 2013 investment picks
2013/5/16
New findings validate clinical utility in Colorectal Cancer Staging MONTREAL , May 16, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"), today announced that results from a large validation study of the Previstage TM GCC Colorectal Cancer Staging Test have been selected for presentation at the 2013 American Society of Clinical Oncology ® (ASCO ® ) Annual Meeting, taking place in Chicago, Illinois from May 31 to June 4, 2013 .
Sign-up for DiagnoCure announces presentation on Previstage GCC at the 2013 ASCO annual meeting investment picks
2013/5/16
LEXINGTON, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS) , an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that a clinical abstract reporting Phase I clinical results of CUDC-427, a small molecule antagonist of IAP proteins, has been selected for oral presentation at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), being held from May 31- June 4 in Chicago, IL.
Sign-up for Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting investment picks
2013/5/15
Synta Pharmaceuticals Corp.
Sign-up for Synta Announces Presentations at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting investment picks
2013/5/15
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical data on Iclusig ® (ponatinib) and AP26113, its investigational inhibitor of anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR) and c-ros oncogene (ROS1), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 31 to June 4, 2013.
Sign-up for ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2013 ASCO Annual Meeting investment picks
2013/5/15
BOSTON, May 15, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Gerald P.
Sign-up for ZIOPHARM Announces Poster Presentation at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Asco Annual Meeting
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ASCO Annual  |  Next: Asia Bond Funds